Dr Reddy’s launches Tobramycin inhalation solution in US

Our Bureau Hyderabad | Updated on June 25, 2019 Published on June 25, 2019

Dr Reddy’s Laboratories Ltd has launched Tobramycin Inhalation Solution, a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration (USFDA).

The TOBI (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million for the twelve months ended April 2019 according to a release from IQVIA Health, the Hyderabad-based company.

Tobi is a trademark of Mylan. Dr Reddy’s Tobramycin Inhalation Solution is available in a 300 mg/5 mL, single-dose Ampule.

Published on June 25, 2019
This article is closed for comments.
Please Email the Editor